Lung (small cell) Cancer Lung (small cell)
Conditions
Interventions
1. Regimen A: Chemotherapy, oral etoposide repeated every 3 weeks for six courses.
2. Regimen B: Multi-drug chemotherapy, CAV (cyclophosphamide, adriamycin, vincristine) alternating every 3 weeks with
Sponsors
UK Co-ordinating Committee for Cancer Research (UKCCCR)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Histologically or cytologically proven SCLC 2. Patients with extensive disease and poor prognosis, i.e., Eastern Cooperative Oncology Group (ECOG) performance 2 or 3 or alkaline phosphatase >1.5 upper limit normal range 3. Patients 75 years and over, whatever stage of disease, deemed fit for randomisation 4. No previous malignancy, except non-melanomatous skin cancer in the preceding 3 years 5. No medical contraindications to treatment 6. Adequate renal function
Exclusion criteria
Exclusion criteria: Not provided at time of registration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed